Encorafenib

Generic name: Encorafenib
Brand names: Braftovi
Dosage form: oral capsule (75 mg)
Drug class: Multikinase inhibitors

Usage of Encorafenib

Encorafenib is used in combination with a medicine called Binimetinib (Mektovi) to treat melanoma (skin cancer) that cannot be treated with surgery or has spread to other parts of the body.

Encorafenib is used in combination with a medicine called Cetuximab (Erbitux) to treat colorectal cancer that has spread to other parts of the body.

Encorafenib is used only if your cancer has a specific genetic marker (an abnormal "BRAF" gene). Your doctor will test you for this gene. encorafenib is not for treating wild-type BRAF cancers.

Encorafenib may also be used for purposes not listed in this medication guide.

Encorafenib side effects

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Some side effects are more likely to occur if you take encorafenib and binimetinib together. Call your doctor at once if you have:

eye pain or swelling, vision changes, seeing halos around lights, seeing color "dots" in your vision;

severe skin rash, skin pain or swelling, redness and peeling skin on your hands or feet;

fast or pounding heartbeats, fluttering in your chest, shortness of breath, and sudden dizziness (like you might pass out); or

signs of bleeding--weakness, dizziness, headache, nosebleeds, rectal bleeding, bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds.

Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.

Common side effects of encorafenib may include:

nausea, vomiting, stomach pain;

tiredness; or

joint pain or swelling.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking Encorafenib

You should not use encorafenib if you are allergic to it.

Tell your doctor if you have ever had:

heart problems;

long QT syndrome (in you or a family member);

lung disease;

liver or kidney disease;

eye problems (especially a problem with your retina); or

bleeding problems, or a blood clot.

Although this medicine is used to treat melanoma, using encorafenib may increase your risk of developing other types of skin cancer. Tell your doctor if you notice any new skin symptoms such as redness, warts, sores that will not heal, or a mole that has changed in size or color.

You may need to have a negative pregnancy test before starting this treatment.

Do not use encorafenib if you are pregnant. It could harm the unborn baby. Use effective birth control to prevent pregnancy while you are using this medicine and for at least 2 weeks after your last dose. Tell your doctor if you become pregnant.

Encorafenib can make hormonal birth control less effective, including birth control pills, injections, implants, skin patches, and vaginal rings. To prevent pregnancy while using encorafenib, use a barrier form of birth control: condom, diaphragm, cervical cap, or contraceptive sponge.

This medicine may affect fertility (ability to have children) in men.

Do not breastfeed while using this medicine, and for at least 2 weeks after your last dose.

Relate drugs

How to use Encorafenib

Usual Adult Dose for Melanoma -- Metastatic:

450 mg orally once a day in combination with binimetinib until disease progression or unacceptable toxicity NOTE: If binimetinib is withheld, reduce encorafenib to a maximum dose of 300 mg once a day until binimetinib is resumed.Comments:-COnfirm the presence of a BRAF V600E or V600K mutation in tumor specimens prior to initiating therapy.-Refer to the binimetinib prescribing information for recommended dosing information.Use: This drug, in combination with binimetinib, is indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test

Usual Adult Dose for Colorectal Cancer:

300 mg orally once a day in combination with cetuximab until disease progression or unacceptable toxicity Comments:-Confirm the presence of a BRAF V600E mutation in tumor specimens prior to initiating therapy.-Refer to the cetuximab prescribing information for recommended dosing information.Use: This drug, in combination with cetuximab, is indicated for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy

Warnings

Encorafenib can harm an unborn baby. Do not use if you are pregnant. Use a non-hormonal form of birth control to prevent pregnancy while using encorafenib and for at least 2 weeks after your last dose.

Although encorafenib is used to treat melanoma, using encorafenib may increase your risk of developing other types of skin cancer. Ask your doctor about your specific risk. Tell your doctor if you notice any new skin symptoms.

What other drugs will affect Encorafenib

Sometimes it is not safe to use certain medications at the same time. Some drugs can affect your blood levels of other drugs you take, which may increase side effects or make the medications less effective.

Other drugs may affect encorafenib, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.